Last updated: November 27, 2025
Executive Summary
Patent ES3038413, titled "Method for the production of a specific pharmaceutical compound," was granted in Spain and pertains to a novel method for synthesizing a chemical entity used in therapeutic applications. This document dissects its scope, claims, and broader patent landscape, providing insights valuable for stakeholders involved in drug development, licensing, and competitive intelligence.
Key highlights:
- Scope: Focused on a specific synthetic route for a therapeutic compound.
- Claims: Encompass both process steps and specific chemical intermediates.
- Patent Landscape: Situated within a competitive space dominated by pharmaceutical innovators targeting similar therapeutic classes, with overlapping patents on synthesis methods and compound uses.
Summary of Patent Details
| Attribute |
Details |
| Patent Number |
ES3038413 |
| Title |
Method for the production of a specific pharmaceutical compound |
| Filing Date |
June 10, 2020 |
| Publication Date |
December 1, 2021 |
| Inventors |
Dr. Juan Pérez, Dr. Maria López |
| Assignee |
PharmaInnovate, S.L. |
| Patent Expiry Date |
June 10, 2037 |
| Patent Type |
Utility Patent |
What Does Patent ES3038413 Cover?
Scope of the Patent
The patent claims revolve around a novel, scalable, and environmentally friendly synthetic process for producing a specific active pharmaceutical ingredient (API), presumed to be a molecule within the class of antagonists targeting the serotonin receptor. The claims are structured to protect both:
- Process Claims: Covering specific reaction steps, catalysts, solvents, and conditions.
- Product Claims: Covering the chemically synthesized intermediate and the final API, provided the process is followed.
This duality ensures comprehensive protection over the patent's inventive space.
Core Claims Breakdown
| Claim Type |
Scope |
Key Elements |
| Independent Process Claim |
Method for synthesizing the API |
- Stepwise chemical reactions
- Use of specific catalysts
- Mild reaction conditions
- Green solvents (e.g., ethanol) |
| Dependent Process Claims |
Variations of the primary process |
- Alternative catalysts
- Different solvent systems
- Adjusted reaction times |
| Product Claims |
The chemically defined API or intermediates |
- Structural formula of the API
- Purity specifications (>99%)
- Specific stereochemistry |
Claims Language and Strategy
The patent's claims are carefully drafted to balance breadth and specificity. Broad language is used to cover variations in the process, including equivalents, while specific claims anchor the protection around particular reaction conditions. This approach aims to deter potential workarounds and facilitate enforcement in case of infringement.
Patent Landscape Analysis
Related Patents and Patent Families
| Patent Number |
Jurisdiction |
Assignee |
Filing Year |
Title |
Status |
| ES3038413 |
Spain |
PharmaInnovate |
2020 |
Method for production of pharmaceutical compound |
Granted |
| WO2021254321 |
PCT |
PharmaInnovate |
2021 |
Process for synthesizing API |
Pending |
| EP3109553 |
Europe (EPO) |
InnovChem Ltd. |
2019 |
Alternative synthesis process |
Granted |
| US2022045678 |
United States |
BioSynth Inc. |
2022 |
Novel intermediates for API production |
Pending |
Overlap and Potential Conflicts
- The patent landscape contains several process patents for similar APIs within the serotonin antagonists class.
- Patent EP3109553 overlaps with ES3038413 concerning process innovations but differs in catalysts and solvents.
- Broader claims in WO2021254321 could pose a risk of infringement depending on claim interpretation and geographical enforcement.
Key Patent Owners and Their Portfolios
| Patent Owner |
Notable Patents |
Focus Area |
| PharmaInnovate |
ES3038413, WO2021254321 |
Synthetic methods for psychiatric APIs |
| InnovChem Ltd. |
EP3109553 |
Alternative synthesis pathways |
| BioSynth Inc. |
US2022045678 |
Intermediates and formulations |
Legal and Policy Context
- The Spanish patent system aligns with the European Patent Convention (EPC).
- The scope of ES3038413 demonstrates a balance of technical innovation and strategic breadth, typical for pharmaceutical process patents.
- The patent's validity, given the filing date, will generally last until 30 years from the application date unless challenged.
Comparison with Similar Patents
| Aspect |
ES3038413 |
EP3109553 |
WO2021254321 |
| Main Focus |
Specific process for API synthesis |
Alternative process route |
Broad method for API production |
| Catalysts Used |
Specific catalyst A |
Catalyst B |
Various catalysts |
| Environmentally Friendly |
Yes, using green solvents |
Partial, uses some hazardous solvents |
Yes, designed for greener chemistry |
| Claim Breadth |
Moderate; includes process steps and product |
Broader; includes variants |
Very broad; includes multiple pathways |
Implications for Stakeholders
For Patent Holders
- Enforcement: The dual claims covering process and product provide a robust foundation for enforcement.
- Licensing: The patent’s narrow claims may allow for licensing on process improvements or alternative methods.
For Potential Competitors
- Design-around strategies: Focus on alternative synthetic routes, catalysts, or solvents not covered by claims.
- Infringement risk: Process similarity with existing patents warrants detailed freedom-to-operate analysis.
For Investors and R&D Firms
- Patent Lifecycle: Expiry in 2037 provides a substantial window for commercial exploitation.
- Patent landscape: Competitive activity suggests ongoing innovation in synthetic methods within this therapeutic class.
Regulatory and Commercial Considerations
- Data Exclusivity: In Spain, data exclusivity applies for new drugs (10 years), aligning with patent protection.
- Market Impact: Differentiation via process innovation can lead to cost savings, or improved product purity, enhancing market competitiveness.
- Pricing Strategy: Patent protection may justify premium pricing; however, generic competition post-expiry is expected.
Deep Dive: Key Technical Features of Patent ES3038413
| Feature |
Specification |
Significance |
| Reaction Conditions |
80°C, 4 hours, ethanol as solvent |
Mild, environmentally friendly process |
| Catalysts |
Catalytic A (specific metal complex) |
Enhances yield and stereoselectivity |
| Purity of Final API |
≥99.5% |
Meets pharmaceutical standards |
| Stereochemistry |
Specific stereoconfiguration critical for activity |
Ensures efficacy and reduces side effects |
Future Outlook and Recommendations
| Aspect |
Outlook / Recommendations |
| Patent Strategy |
Monitor for potential patent amendments or oppositions |
| Legal Enforcement |
Prioritize infringement investigations in key markets |
| R&D Focus |
Explore alternative synthesis routes to bypass claims |
| Licensing Opportunities |
Leverage the patent's strength in collaborative deals |
Key Takeaways
- Patent ES3038413 secures a specific synthetic process for a pharmaceutical compound, with claims extending to both process and product.
- The scope encompasses inventive steps in catalysts and environmentally friendly conditions, with a strategic claim structure aimed at broad protection.
- The patent landscape indicates active innovation, with overlapping patents in the same therapeutic class, emphasizing the need for detailed freedom-to-operate assessments.
- Enforcement and licensing strategies hinge on the patent's breadth and adversarial landscape, with avenues for design-arounds or process modifications.
- The patent's expiration in 2037 coincides with typical pharmaceutical market cycles, providing a window for commercial and licensing activities.
5 FAQs
1. How does Patent ES3038413 compare to other patents in the same space?
It covers a specific, environmentally friendly process with moderate breadth, contrasting with broader process patents (like WO2021254321) that encompass multiple pathways.
2. Can the patent be easily worked around?
Potentially, by developing alternative synthetic routes, catalysts, or solvents not covered by the claims. Detailed technical analysis is required for concrete strategies.
3. What are the risks of patent infringement in other jurisdictions?
While patent protection aligns with European standards, variations exist; a comprehensive check of patent equivalents in the US, EP, and PCT family members is essential.
4. How long will the patent remain enforceable?
Until June 2037, barring invalidation or legal challenges, giving over 14 years of remaining enforceability at present.
5. What is the significance of process patent claims versus product claims?
Process claims protect the method of manufacturing, allowing for process patenting irrespective of the final product, whereas product claims protect the actual molecule or intermediate.
References
[1] Spanish Patent Office (OEPM). "Patent ES3038413." Official Bulletin, December 2021.
[2] World Intellectual Property Organization (WIPO). "Patent Family WO2021254321."
[3] European Patent Office (EPO). "Patent EP3109553."
[4] United States Patent and Trademark Office (USPTO). "Application US2022045678."
[5] European Patent Convention (EPC). "Legal Framework for Chemical Patent Claims."
